Alabama wins second Medicaid fraud verdict
Executive Summary
An Alabama state court jury finds GlaxoSmithKline and Novartis liable for $80.9 million and $33.2 million in compensatory damages, respectively, for inflating the average wholesale prices of prescription drugs. GSK and Novartis announced they would appeal the verdict. The Attorney General of Alabama has sued 79 pharmaceutical companies for overcharging the state Medicaid agency. In February a jury issued a $215 million verdict against AstraZeneca, which a judge subsequently reduced to $160 million (1"The Pink Sheet," June 23, 2008, In Brief)
You may also be interested in...
Three AWP Verdicts Overturned By Alabama Supreme Court; Ruling Could End 70 Other Suits
AstraZeneca, Novartis and GlaxoSmithKline get verdicts totaling $274 million reversed.
AstraZeneca Medicaid fraud verdict
An Alabama state judge upholds a jury verdict that found AstraZeneca reported false and misleading drug prices for reimbursement by Alabama's state Medicaid agency. Judge Charles Price let stand the $40 million award of compensatory damages but lowered the $175 million punitive damages award to $120 million. The attorney general of Alabama has sued about 70 drug companies alleging Medicaid fraud. The suit against AstraZeneca was the first to go to trial. Novartis and GlaxoSmithKline are currently on trial before Judge Price in Montgomery County Circuit Court
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.